Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
The company had reported a loss of 80 cents per share in the year-ago quarter. Revenues in the first quarter totaled $69.2 million, up almost 118.9% year over year. The figure, however, missed the Zacks Consensus Estimate of $70 million. The top line comprised Livmarli (maralixibat) sales, newly acquired Cholbam and Chenodal sales and minimal license and other revenues. Mirum acquired Travere Therapeutics' bile acid products in August 2023, which added the latter's Cholbam capsules and Chenodal tablets to its portfolio of commercialized drugs. Quarter in Detail Livmarli's net product sales were $42.8 million in the first quarter, reflecting an increase of almost 47% year over year. Net product sales of newly acquired Cholbam and Chenodal were $26.1 million, representing the sales of these two products under Mirum's leadership. License and other revenues were $0.3 million in the reported quarter compared with $2.5 million reported in the year-ago quarter. Research and dev
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual MeetingBusiness Wire
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at Morgan Stanley from $57.00 to $53.00. They now have an "overweight" rating on the stock.MarketBeat
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at JMP Securities from $72.00 to $66.00. They now have a "market outperform" rating on the stock.MarketBeat
MIRM
Earnings
- 5/8/24 - Miss
MIRM
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- MIRM's page on the SEC website